Xiang Jing, Si Jinfei, Hao Yue, Wei Jingwen, Wang Wenxian, Guan Yelan, Xu Chunwei, Song Zhengbo
The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Transl Cancer Res. 2023 Mar 31;12(3):550-557. doi: 10.21037/tcr-22-2192. Epub 2023 Mar 17.
Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown promising antitumor activity against a range of advanced cancers. However, evidence is lacking as to whether this combination therapy could benefit thymic epithelial tumors (TETs). We aimed to explore the efficacy and safety of this combination therapy in advanced TETs.
Ten patients with pathologically proven advanced TETs who received ICIs combined with an antiangiogenic agent from 2020 to 2022 at Zhejiang Cancer Hospital were included in the study. The Kaplan-Meier method was used to compare the treatment efficacy and survival outcomes.
Of the cohort of ten patients who received immunotherapy combined with antiangiogenic targeting drugs, two patients achieved a partial response (PR) with an objective response rate of 20% and seven patients achieved stable disease (SD) with a disease control rate (DCR) of 90%. The median progression-free survival (PFS) was 6.7 months [95% confidence interval (CI): 3.35-8.515] and the median overall survival (OS) was 45.6 months (95% CI: 3.265-88.001). Grade 3 treatment-related adverse events (TRAEs) were only detected in one patient. No grade 4 or above TRAEs were observed.
ICIs in combination with antiangiogenic targeted drugs may be a promising treatment for advanced TETs.
免疫检查点抑制剂（ICIs）联合抗血管生成疗法已显示出对一系列晚期癌症具有有前景的抗肿瘤活性。然而，关于这种联合疗法是否能使胸腺上皮肿瘤（TETs）获益，目前尚缺乏证据。我们旨在探讨这种联合疗法在晚期TETs中的疗效和安全性。
本研究纳入了2020年至2022年期间在浙江省肿瘤医院接受ICIs联合抗血管生成药物治疗的10例经病理证实的晚期TETs患者。采用Kaplan-Meier法比较治疗疗效和生存结果。
在接受免疫治疗联合抗血管生成靶向药物治疗的10例患者队列中，2例患者达到部分缓解（PR），客观缓解率为20%，7例患者病情稳定（SD），疾病控制率（DCR）为90%。中位无进展生存期（PFS）为6.7个月[95%置信区间（CI）：3.35 - 8.515]，中位总生存期（OS）为45.6个月（95%CI：3.265 - 88.001）。仅1例患者检测到3级治疗相关不良事件（TRAEs）。未观察到4级及以上TRAEs。
ICIs联合抗血管生成靶向药物可能是晚期TETs的一种有前景的治疗方法。
